GSE249573 Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies [RNA-seq]
Contributors : Kornelia Polyak ; Marie-Anne Goyette ; Laura StevensSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensIn a 3D coculture with stroma cells derived from breast cancer patients ’ brain metastasis, HER2+ breast cancer cells were protected from HER2-targeted therapies, particularly the EGFR/HER2 small molecule inhibitor neratinib. To get insight into how this protection arises, a Synthetic Notch (SynNotch) reporter model allowed to study the effect of direct contact betwee n stroma and cancer cells. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE249459 Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies [ATAC-seq]
Contributors : Kornelia Polyak ; Marie-Anne Goyette ; Laura StevensSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensIn a 3D coculture with stroma cells derived from breast cancer patients ’ brain metastasis, HER2+ breast cancer cells were protected from HER2-targeted therapies, particularly the EGFR/HER2 small molecule inhibitor neratinib. To get insight into how this protection arises, ATAC-seq on coculture cells with or without neratinib as performed. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
ConclusionsIn our cohort, HER2-low TNBC patients exhibits specific clinical characteristics and response features to NAC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 24, 2024 Category: Cancer & Oncology Source Type: research
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
CONCLUSION: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.PMID:38652877 | DOI:10.1200/JCO.23.01909 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Ian E Krop Takahiro Kogawa Dejan Juric Anthony W Tolcher Erika P Hamilton Toru Mukohara Aaron Lisberg Toshio Shimizu Alexander I Spira Junji Tsurutani Senthil Damodaran Kyriakos P Papadopoulos Jonathan Greenberg Fumiaki Kobayashi Hong Zebger Source Type: research
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
CONCLUSION: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.PMID:38652877 | DOI:10.1200/JCO.23.01909 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Ian E Krop Takahiro Kogawa Dejan Juric Anthony W Tolcher Erika P Hamilton Toru Mukohara Aaron Lisberg Toshio Shimizu Alexander I Spira Junji Tsurutani Senthil Damodaran Kyriakos P Papadopoulos Jonathan Greenberg Fumiaki Kobayashi Hong Zebger Source Type: research
Brystkreft hos menn – histopatologi og biomarkører
Tidsskr Nor Laegeforen. 2024 Mar 27;144(5). doi: 10.4045/tidsskr.23.0438. Print 2024 Apr 23.ABSTRACTBACKGROUND: Breast cancer in men accounts for around 1 % of all cases of the disease. The study aimed to identify histopathological parameters and selected biomarkers in men with breast cancer.MATERIAL AND METHOD: Retrospective study of archival material from 53 men diagnosed with breast cancer at the department of pathology, Haukeland University Hospital, in the period 1996-2020. The prevalence of the oestrogen receptor (ER), progesterone receptor (PGR) and Human Epidermal Growth Factor (HER2) biomarkers was examined.RESULT...
Source: Tidsskrift for den Norske Laegeforening - April 23, 2024 Category: General Medicine Authors: Ingvild Kathrin Lok øy Inga Sofie Bakken Elisabeth Wik Ingunn Marie Stefansson Source Type: research
A ratiometric electrochemical biosensor based on ARGET ATRP for detection of HER2 gene
Talanta. 2024 Apr 22;275:126130. doi: 10.1016/j.talanta.2024.126130. Online ahead of print.ABSTRACTHuman epidermal growth factor receptor 2 (HER2), a common proto-oncogene, is overexpressed in a subset of breast cancer patients. It is essential to track HER2 expression for early breast cancer diagnosis. Herein, a ratiometric electrochemical biosensor for detection of HER2 based on activators generated by electron transfer for atom transfer radical polymerisation (AGET ATRP) and hairpin DNA was developed. Specifically, hairpin DNA was first self-assembled on the gold electrode by Au-S bond. Upon capturing HER2, the stem-loo...
Source: Talanta - April 23, 2024 Category: Chemistry Authors: Aozi Feng Li Li Ningxia He Daoxiang Li Danna Zheng Yanju Liu Huaixia Yang Source Type: research
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
CONCLUSION: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.PMID:38652877 | DOI:10.1200/JCO.23.01909 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Ian E Krop Takahiro Kogawa Dejan Juric Anthony W Tolcher Erika P Hamilton Toru Mukohara Aaron Lisberg Toshio Shimizu Alexander I Spira Junji Tsurutani Senthil Damodaran Kyriakos P Papadopoulos Jonathan Greenberg Fumiaki Kobayashi Hong Zebger Source Type: research
Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey
CONCLUSION: In the context of early-stage HER2+ breast cancer in Spain, a notable diversity in therapeutic approaches was observed. The majority of interviewed medical oncologists acknowledged HER2DX as a clinically valuable test for specific patients, in line with the 2022 SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer. To facilitate the full integration of HER2DX into clinical guidelines, conducting prospective studies to further validate its efficacy and utility was recommended.PMID:38653928 | DOI:10.1007/s12094-024-03409-4 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Olga Mart ínez-Sáez Javier Cort és Eva Ciruelos Mercedes Mar ín-Aguilera Gloria Gonz ález Laia Par é Adriana Herrera Patricia Villagrasa-Gonz ález Aleix Prat Miguel Mart ín Source Type: research
Brystkreft hos menn – histopatologi og biomarkører
Tidsskr Nor Laegeforen. 2024 Mar 27;144(5). doi: 10.4045/tidsskr.23.0438. Print 2024 Apr 23.ABSTRACTBACKGROUND: Breast cancer in men accounts for around 1 % of all cases of the disease. The study aimed to identify histopathological parameters and selected biomarkers in men with breast cancer.MATERIAL AND METHOD: Retrospective study of archival material from 53 men diagnosed with breast cancer at the department of pathology, Haukeland University Hospital, in the period 1996-2020. The prevalence of the oestrogen receptor (ER), progesterone receptor (PGR) and Human Epidermal Growth Factor (HER2) biomarkers was examined.RESULT...
Source: Tidsskrift for den Norske Laegeforening - April 23, 2024 Category: General Medicine Authors: Ingvild Kathrin Lok øy Inga Sofie Bakken Elisabeth Wik Ingunn Marie Stefansson Source Type: research
A ratiometric electrochemical biosensor based on ARGET ATRP for detection of HER2 gene
Talanta. 2024 Apr 22;275:126130. doi: 10.1016/j.talanta.2024.126130. Online ahead of print.ABSTRACTHuman epidermal growth factor receptor 2 (HER2), a common proto-oncogene, is overexpressed in a subset of breast cancer patients. It is essential to track HER2 expression for early breast cancer diagnosis. Herein, a ratiometric electrochemical biosensor for detection of HER2 based on activators generated by electron transfer for atom transfer radical polymerisation (AGET ATRP) and hairpin DNA was developed. Specifically, hairpin DNA was first self-assembled on the gold electrode by Au-S bond. Upon capturing HER2, the stem-loo...
Source: Talanta - April 23, 2024 Category: Chemistry Authors: Aozi Feng Li Li Ningxia He Daoxiang Li Danna Zheng Yanju Liu Huaixia Yang Source Type: research
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
CONCLUSION: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.PMID:38652877 | DOI:10.1200/JCO.23.01909 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Ian E Krop Takahiro Kogawa Dejan Juric Anthony W Tolcher Erika P Hamilton Toru Mukohara Aaron Lisberg Toshio Shimizu Alexander I Spira Junji Tsurutani Senthil Damodaran Kyriakos P Papadopoulos Jonathan Greenberg Fumiaki Kobayashi Hong Zebger Source Type: research
Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey
CONCLUSION: In the context of early-stage HER2+ breast cancer in Spain, a notable diversity in therapeutic approaches was observed. The majority of interviewed medical oncologists acknowledged HER2DX as a clinically valuable test for specific patients, in line with the 2022 SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer. To facilitate the full integration of HER2DX into clinical guidelines, conducting prospective studies to further validate its efficacy and utility was recommended.PMID:38653928 | DOI:10.1007/s12094-024-03409-4 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Olga Mart ínez-Sáez Javier Cort és Eva Ciruelos Mercedes Mar ín-Aguilera Gloria Gonz ález Laia Par é Adriana Herrera Patricia Villagrasa-Gonz ález Aleix Prat Miguel Mart ín Source Type: research
Brystkreft hos menn – histopatologi og biomarkører
Tidsskr Nor Laegeforen. 2024 Mar 27;144(5). doi: 10.4045/tidsskr.23.0438. Print 2024 Apr 23.ABSTRACTBACKGROUND: Breast cancer in men accounts for around 1 % of all cases of the disease. The study aimed to identify histopathological parameters and selected biomarkers in men with breast cancer.MATERIAL AND METHOD: Retrospective study of archival material from 53 men diagnosed with breast cancer at the department of pathology, Haukeland University Hospital, in the period 1996-2020. The prevalence of the oestrogen receptor (ER), progesterone receptor (PGR) and Human Epidermal Growth Factor (HER2) biomarkers was examined.RESULT...
Source: Tidsskrift for den Norske Laegeforening - April 23, 2024 Category: General Medicine Authors: Ingvild Kathrin Lok øy Inga Sofie Bakken Elisabeth Wik Ingunn Marie Stefansson Source Type: research
Brystkreft hos menn – histopatologi og biomarkører
Tidsskr Nor Laegeforen. 2024 Mar 27;144(5). doi: 10.4045/tidsskr.23.0438. Print 2024 Apr 23.ABSTRACTBACKGROUND: Breast cancer in men accounts for around 1 % of all cases of the disease. The study aimed to identify histopathological parameters and selected biomarkers in men with breast cancer.MATERIAL AND METHOD: Retrospective study of archival material from 53 men diagnosed with breast cancer at the department of pathology, Haukeland University Hospital, in the period 1996-2020. The prevalence of the oestrogen receptor (ER), progesterone receptor (PGR) and Human Epidermal Growth Factor (HER2) biomarkers was examined.RESULT...
Source: Tidsskrift for den Norske Laegeforening - April 23, 2024 Category: General Medicine Authors: Ingvild Kathrin Lok øy Inga Sofie Bakken Elisabeth Wik Ingunn Marie Stefansson Source Type: research
